Botulinum toxin type A for drooling in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study | Zendy

Lagalla Giovanni | Zendy; Millevolte Marzia | Zendy; Capecci Marianna | Zendy; Provinciali Leandro | Zendy; Ceravolo Maria Gabriella | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Botulinum toxin type A for drooling in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study

Author(s) -

Lagalla Giovanni,

Millevolte Marzia,

Capecci Marianna,

Provinciali Leandro,

Ceravolo Maria Gabriella

Publication year - 2006

Publication title -

movement disorders

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.352

H-Index - 198

eISSN - 1531-8257

pISSN - 0885-3185

DOI - 10.1002/mds.20793

Subject(s) - drooling , sialorrhea , placebo , medicine , botulinum toxin , parkinson's disease , adverse effect , anesthesia , randomized controlled trial , surgery , disease , pathology , alternative medicine

To investigate the safety and efficacy of botulinum toxin type A (BoNTX) treatment to reduce sialorrhea in Parkinson's disease (PD), a double‐blind, randomized, placebo‐controlled study enrolled 32 PD patients complaining of excessive drooling. Patients received either 50 U Botox in each parotid gland or placebo without using ultrasound guidance. Subjects treated with BoNTX experienced a reduction in both drooling frequency and familial and social disability (Time × Group effect: P < 0.01), as well as in saliva production (Time × Group effect: P < 0.0001). No adverse events were recorded. BoNTX injections are safe and effective treatment for the management of PD‐related drooling. © 2006 Movement Disorder Society

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research